Alleviation of Radiation Lung Damage by Administration of Gene-Modified Mesenchymal Stem Cells.

J. Xue,Y. Lu,X. Li,Y. Zhang,R. Ao,Y. Wang,H. Liu,Y. Wu,X. Mo
DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.e13568
IF: 45.3
2010-01-01
Journal of Clinical Oncology
Abstract:e13568 Background: Radiation pneumonitis (RP) and subsequent radiation pulmonary fibrosis (RPF) is a common and serious complication in the treatment with radiation therapy (RT) for lung cancer. In order to investigate the alleviation efficacy by gene-modified mesenchymal stem cells (MSCs), we assessed whether adenovirus-transduced MSCs with the soluble transforming growth factor-beta type II receptor (Ad-sTβR) could reduce RP and RFP. Methods: MSCs from male C57BL/6 mice were isolated and verified. The whole lung of each female C57BL/6 mouse was irradiated with a single dose of 14Gy. Injection of PBS, Ad-sTβR, MSCs, and Ad-sTβR-transduced MSCs (Ad-sTβR-MSCs) by tail vein were administrated immediately and 14 days after radiation, respectively. RP and RPF were assessed by H&E, Masson trichrome staining, MDA, hydroxyproline and TGF-β1 assay as well as quantitative RT-PCR and Western Blot for CTGF and α-SMA. Furthermore, the differentiation assays of male MSCs into type II pneumocytes were performed by Real...
What problem does this paper attempt to address?